M&G plc’s Krystal Biotech KRYS Stock Holding History

M&G plc’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,748	Closed	-$924K	–	426
2025 Q2	$924K	Buy	+6,748	New	+$991K	0.01%	335

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

M&G plc's KRYS Position: Q3 2025 in Review

M&G plc sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 6,748 shares — an estimated $924K sold.

M&G plc first reported a position in KRYS in Q2 2025 and held it in 1 quarter. The position peaked at $924K in Q2 2025. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

M&G plc reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
M&G plc sold 6,748 Krystal Biotech shares in Q3 2025, an estimated $924K.
M&G plc first reported a position in Krystal Biotech in Q2 2025 and held it in 1 quarter.
M&G plc's Krystal Biotech position peaked at $924K in Q2 2025.
284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on M&G plc's 13F filing for Q3 2025, filed 7 Nov 2025.